Get the Stockscreener App
26.35
1.64%
-0.44
After Hours:
26.35
Rapt Therapeutics Inc stock is traded at $26.35, with a volume of 264.15K.
It is down -1.64% in the last 24 hours and up +62.45% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$26.79
Open:
$27.41
24h Volume:
264.15K
Relative Volume:
1.49
Market Cap:
$435.77M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-8.6393
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
-11.78%
1M Performance:
+62.45%
6M Performance:
+281.44%
1Y Performance:
+80.98%
1-Day Range:
$24.25
$27.41
1-Week Range:
$24.25
$30.93
52-Week Range:
$5.6652
$32.35
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
26.35 | 443.05M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-26-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
Why retail investors favor RAPT Therapeutics Inc. stockEarnings Growth Summary & Fast Exit/Entry Strategy Plans - newser.com
Is RAPT Therapeutics Inc. stock a buy for dividend growthJuly 2025 Summary & Free Daily Entry Point Trade Alerts - newser.com
Risk adjusted return profile for RAPT Therapeutics Inc. analyzed2025 Key Highlights & AI Enhanced Trading Signals - newser.com
What indicators show strength in RAPT Therapeutics Inc.July 2025 Institutional & Fast Gain Stock Trading Tips - newser.com
What MACD and RSI say about RAPT Therapeutics Inc.Sell Signal & Weekly Return Optimization Alerts - newser.com
Will RAPT Therapeutics Inc. price bounce be sustainableMarket Sentiment Report & Consistent Income Trade Recommendations - newser.com
Key metrics from RAPT Therapeutics Inc.’s quarterly dataPortfolio Return Report & High Yield Equity Trading Tips - newser.com
Top chart patterns to watch in RAPT Therapeutics Inc.Layoff News & Free Weekly Chart Analysis and Trade Guides - newser.com
What hedge fund moves indicate for RAPT Therapeutics Inc. (0RA) stockTrade Volume Summary & Consistent Profit Alerts - newser.com
Market reaction to RAPT Therapeutics Inc.’s recent newsRate Hike & Reliable Price Breakout Signals - newser.com
Why RAPT Therapeutics Inc. stock is seen as undervalued2025 Biggest Moves & Free Safe Capital Growth Stock Tips - newser.com
Rapt Therapeutics (NASDAQ:RAPT) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Does RAPT Therapeutics Inc. qualify in momentum factor screening2025 Macro Impact & Breakout Confirmation Trade Signals - newser.com
What drives RAPT Therapeutics Inc 0RA0 stock priceTrade Execution Strategies & Identify Winning Stocks - earlytimes.in
Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
How analysts rate RAPT Therapeutics Inc. stock today2025 Institutional Moves & Detailed Earnings Play Strategies - newser.com
How to use a screener to detect RAPT Therapeutics Inc. breakoutsPortfolio Profit Report & Long Hold Capital Preservation Tips - newser.com
Can swing trading help recover from RAPT Therapeutics Inc. lossesWeekly Gains Report & High Accuracy Trade Signal Alerts - newser.com
Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Why RAPT Therapeutics Inc. (0RA0) stock stays on top picksWeekly Gains Report & Free Daily Entry Point Trade Alerts - newser.com
Is RAPT Therapeutics Inc. (0RA) stock bottoming after sell offQuarterly Profit Summary & High Conviction Buy Zone Picks - newser.com
Rapt Therapeutics (NASDAQ:RAPT) Sets New 12-Month HighTime to Buy? - MarketBeat
How RAPT Therapeutics Inc. (0RA) stock performs in volatility spikesJuly 2025 Big Picture & Real-Time Chart Breakout Alerts - newser.com
Will RAPT Therapeutics Inc. stock maintain growth story2025 Technical Patterns & Reliable Price Action Trade Plans - newser.com
Published on: 2025-10-02 21:38:33 - newser.com
Will RAPT Therapeutics Inc. (0RA) stock draw ESG focused fundsRisk Management & Daily Profit Focused Screening - newser.com
Clear Street Maintains RAPT Therapeutics (RAPT) Buy Recommendation - Nasdaq
Clear Street Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Maintains Target Price $41 - 富途牛牛
Published on: 2025-09-30 02:47:57 - newser.com
RAPT Therapeutics stock rises after FDA clears IND for food allergy trial - Investing.com Australia
Clear Street Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Raises Target Price to $41 - 富途牛牛
Rapt Therapeutics stock price target raised to $41 from $24 at Clear Street - Investing.com Canada
RAPT Therapeutics stock rises after FDA clears IND for food allergy trial By Investing.com - Investing.com Nigeria
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):